Literature DB >> 7512981

Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells.

T Shoshani1, E Kerem, A Szeinberg, A Augarten, Y Yahav, D Cohen, J Rivlin, A Tal, B Kerem.   

Abstract

The effect of nonsense mutations on mRNA levels is variable. The levels of some mRNAs are not affected and truncated proteins are produced, while the levels of others are severely decreased and null phenotypes are observed. The effect on mRNA levels is important for the understanding of phenotype-genotype association. Cystic fibrosis (CF) is a lethal autosomal recessive disease with variable clinical presentation. Recently, two CF patients with mild pulmonary disease carrying nonsense mutations (R553X, W1316X) were found to have severe deficiency of mRNA. In the Jewish Ashkenazi CF patient population, 60% of the chromosomes carry a nonsense mutation, W1282X. Patients homozygous for this mutation have severe disease presentation with variable pulmonary disease. The presence of CF transcripts in a group of patients homozygous and heterozygous for this mutation was studied by reverse transcriptase PCR of various regions of the gene. Subsequent hybridization to specific CF PCR probes and densitometry analysis indicated that the CF mRNA levels in patients homozygous for the W1282X mutation are not significantly decreased by the mutation. mRNA levels were compared for patients heterozygous for the W1282X mutation. The relative levels of mRNA with the W1282X, and the delta F508 or the normal alleles, were similar in each patient. These results indicate that the severe clinical phenotype of patients carrying the W1282X mutation is not due to a severe deficiency of mRNA. In addition, the severity, progression, and variability of the pulmonary disease are affected by other, as yet unknown factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512981      PMCID: PMC294164          DOI: 10.1172/JCI117128

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

Authors:  E Kerem; M Corey; B S Kerem; J Rommens; D Markiewicz; H Levison; L C Tsui; P Durie
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

Review 2.  Regulated mRNA stability.

Authors:  J A Atwater; R Wisdom; I M Verma
Journal:  Annu Rev Genet       Date:  1990       Impact factor: 16.830

3.  Identification of the cystic fibrosis gene: genetic analysis.

Authors:  B Kerem; J M Rommens; J A Buchanan; D Markiewicz; T K Cox; A Chakravarti; M Buchwald; L C Tsui
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

5.  An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide.

Authors:  P R Winship
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

6.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

7.  Nonsense mutations in the dihydrofolate reductase gene affect RNA processing.

Authors:  G Urlaub; P J Mitchell; C J Ciudad; L A Chasin
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

8.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

9.  Premature translation termination mediates triosephosphate isomerase mRNA degradation.

Authors:  I O Daar; L E Maquat
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

10.  Linked marker haplotypes and the delta F508 mutation in adults with mild pulmonary disease and cystic fibrosis.

Authors:  G Santis; L Osborne; R A Knight; M E Hodson
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

View more
  7 in total

Review 1.  Novel pharmacologic therapies for cystic fibrosis.

Authors:  P L Zeitlin
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

2.  Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.

Authors:  Jeyakumar Kandasamy; Dana Atia-Glikin; Eli Shulman; Katya Shapira; Michal Shavit; Valery Belakhov; Timor Baasov
Journal:  J Med Chem       Date:  2012-11-29       Impact factor: 7.446

3.  Update and Review: Cystic Fibrosis.

Authors:  T Brown; E L Schwind
Journal:  J Genet Couns       Date:  1999-06       Impact factor: 2.537

4.  Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.

Authors:  Steven M Rowe; Peter Sloane; Li Ping Tang; Kyle Backer; Marina Mazur; Jessica Buckley-Lanier; Igor Nudelman; Valery Belakhov; Zsuzsa Bebok; Erik Schwiebert; Timor Baasov; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2011-07-22       Impact factor: 4.599

5.  New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.

Authors:  Keisuke Hamada; Noriko Omura; Akihiro Taguchi; Alireza Baradaran-Heravi; Masaya Kotake; Misaki Arai; Kentaro Takayama; Atsuhiko Taniguchi; Michel Roberge; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2019-09-23       Impact factor: 4.345

6.  Restoration of W1282X CFTR activity by enhanced expression.

Authors:  Steven M Rowe; Karoly Varga; Andras Rab; Zsuzsa Bebok; Kevin Byram; Yao Li; Eric J Sorscher; John P Clancy
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-31       Impact factor: 6.914

Review 7.  Cystic Fibrosis, CFTR, and Colorectal Cancer.

Authors:  Patricia Scott; Kyle Anderson; Mekhla Singhania; Robert Cormier
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.